Evidence map›Paper›PMID 38984583›Full record

ArticleCurrent medicinal chemistry2025

Post-COVID-19: Hematological Factors Changes in Patients at Three-time Intervals.

Mohsen Sharif-Zak, Mojtaba Abbasi-Jorjandi, Gholamreza Asadikaram, Zohreh-Al-Sadat Ghoreshi, Moslem Abolhassani, Clifford Rosen

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohsen Sharif-ZakDepartment of Clinical Biochemistry, Applied Cellular and Molecular Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Mojtaba Abbasi-JorjandiDepartment of Clinical Biochemistry, Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran.
Gholamreza AsadikaramDepartment of Clinical Biochemistry, Applied Cellular and Molecular Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Zohreh-Al-Sadat GhoreshiDepartment of Clinical Biochemistry, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Moslem AbolhassaniDepartment of Clinical Biochemistry, Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran.
Clifford RosenMaineHealth Institue for Research, Scarborough, Maine, 04074, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHematological parameters are crucial factors in disease severity and chronic condition pathogenesis. We aimed to evaluate the hematological factors in different severity stages of COVID-19 at different time intervals.

methodsSerum samples were collected from 470 patients (235 men and 235 women) with a confirmed RT-qPCR COVID-19 test exhibiting moderate, severe, and critical symptoms based on WHO criteria. Samples were collected at three-time intervals, including the first: the 1

resultsTotal WBC, neutrophil, lymphocyte, platelet, RBC counting, Hb, HCT, MCV, MCH, and hsCRP levels were significantly changed with different disease severity (p<0.0001). Also, there were significant differences between different time intervals for WBC and RBC parameters (p<0.0001) except for monocytes and eosinophils. At all time intervals, there are significant changes in levels of hematological and hsCRP based on gender. Moreover, a significant correlation was observed between disease severity, age, and BMI (p<0.0001).

conclusionSignificant differences in hematological parameter and inflammatory parameter levels based on disease severity, time intervals, and gender revealed the importance of evaluating these factors in the management of infectious diseases, such as COVID-19, in patients during and post-disease times.

Indexed as

COVID-19AdultAgedC-Reactive ProteinFemaleHumansLeukocyte CountMaleMiddle AgedSARS-CoV-2Severity of Illness IndexTime FactorsC-Reactive Proteinchronic conditionCOVID-19hcCRP.Hematological parametersRBCWBC

Identifiers

PMID38984583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.